Physician profile
John L Briggs
NPI 1598748220
$2,378.10
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $682 · 2021: $929 · 2022: $132.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $503.37 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $380.17 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $182.97 | 2019-2021 | |
| Glaxosmithkline, LLC. | $161.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.68 | 2019-2021 | |
| Abbvie INC. | $125.17 | 2021-2022 | |
| Lilly USA, LLC | $110.17 | 2020-2021 | |
| Pfizer INC. | $104.71 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $76.36 | 2021-2022 | |
| Abbott Laboratories | $75.18 | 2021-2022 | |
| Amgen INC. | $65.34 | 2019-2020 | |
| Viiv Healthcare Company | $58.43 | 2020-2021 | |
| Amarin Pharma, INC. | $49.73 | 2020-2021 | |
| Allergan, INC. | $34.39 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.23 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $28.38 | 2021 | |
| Merck Sharp & Dohme LLC | $27.79 | 2021 | |
| Sanofi Pasteur INC. | $26.06 | 2019-2020 | |
| Gilead Sciences, INC. | $23.46 | 2021 | |
| Melinta Therapeutics, LLC | $21.81 | 2022 | |
| Cranial Technologies, INC | $17.33 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.75 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.48 | 2021 | |
| Mylan Specialty L.P. | $12.98 | 2021 | |
| Theratechnologies INC. | $11.91 | 2021 | |
| Hikma Pharmaceuticals USA | $11.51 | 2019 | |
| Circassia INC. | $11.10 | 2019 | |
| Shire North American Group INC | $11.03 | 2019 | |
| Seqirus USA INC | $11.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Briggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.